Metabolism of chylomicron-like emulsions in carriers of the S447X lipoprotein lipase polymorphism

Clinica Chimica Acta

Volumn 335, Issue 1-2, 2003, Pages 157-163

  Almeida, Katia A ^a   Schreiber, Roberto ^a   Amâncio, Rosângela F ^a   Bydlowski, Sérgio P ^a   Debes Bravo, Adriana ^a   Issa, Jacqueline S ^a   Strunz, Célia M C ^a   Maranhão, Raul C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cholesterol; Chylomicrons; Coronary artery disease; Emulsions; Enzyme mutations; Lipoprotein lipase; Triglycerides

Indexed keywords

CARBON 14; CHOLESTEROL OLEATE; CHYLOMICRON; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL; TRITIUM;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CLEARANCE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; RADIATION MEASUREMENT; RISK FACTOR;

EID: 0242285695     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00289-4     Document Type: Article

References (33)

1. Goldberg I.J. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J. Lipid Res. 37:1996;693-707.
2. Mahley R.W., Chin-On S., Hofman A., Cresswell S.R., Havekes L. Post-prandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler. Thromb. 11:1991;653-662.
3. Cooper A.D. Hepatic uptake of chylomicron remnants. J. Lipid Res. 38:1997;2173-2192.
4. Simons L.A., Dwyer T., Simons J., Bernstein L., Mock P., Poonia N.S.et al. Chylomicrons and chylomicron remants in coronary artery disease: a case-control study. Atherosclerosis. 65:1987;181.
5. Simpson H.S., Williamson C.M., Olivecrona T., Pringle S., Maclean J., Lorimar A.R.et al. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis. 85:1990;193.
6. Groot P.H., Van Stiphout W.A.C.J., Krauss X.H., Jansen H., Van Tol A., Van Ramshorst E.et al. Post-prandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler. Thromb. 11:1991;53-62.
7. Patsch J.R., Miesenbock G., Hopferwieser T., Muhlberger V., Knapp E., Dunn J.K. Gotto Relation of triglyceride metabolism and coronary artery disease: studies in post-prandial state. Arterioscler. Thromb. 2:1992;1336-1345.
8. Weintraub M.S., Grosskopf I., Rassin T., Miller H., Charach G., Rotmensch H.H.et al. Clearance of chylomicron remnants in normolipidemic patients with coronary artery disease: case control study over 3 years. Br. Med. J. 312:1996;935-939.
9. Maranhão R.C., Feres M.C., Martins M.T., Mesquita C.H., Toffoletto O., Vinagre C.G.et al. Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. Atherosclerosis. 126:1996;15-25.
10. Fisher R.M., Humphries S.E., Talmud P.J. Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis. 135:1997;145-159.
11. Wittrup H.H., Tybjaerg-Hansen A., Nordestgaard B.G. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 99:1999;2901-2907.
12. Hata A., Robertson M., Emi M., Lalouel J.M. Direct detection and automated sequencing of individual alleles after electrophoretic strand separation: identification of a common nonsense mutation in exon 9 of the human lipoprotein lipase gene. Nucleic Acids Res. 18:1990;5407-5411.
13. Gagne S.E., Larson M.G., Pimstone S.N., Schaefer E.J., Kastelein J.J., Wilson P.W.et al. A common truncation variant of lipoprotein lipase (S447XX) confers protection against coronary heart disease: the Framingham Offspring Study. Clin. Genet. 55:1999;450-454.
14. Kuivenhoven J.A., Groenemeyer B.E., Boer J.M.A., Reymer P.W.A., Berghuis R., Bruin T.et al. S447X stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males. Arterioscler. Thromb. Vasc. Biol. 17:1997;595-599.
15. Jemaa R., Fumeron F., Poirier O., Lecerf L., Evans A., Arveiler D.et al. Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude cas temoin sur l'Infarctus du myocarde. J. Lipid Res. 36:1995;2141-2146.
16. Salah D., Bohnet K., Gueguen R., Siest G., Visvikis S. Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein levels in the Stanislas cohort. J. Lipid Res. 38:1997;904-912.
17. Groenemeijer B.E., Hollman M.D., Reymen P.W., Gayne E., Kuivenhoven J.A., Bruin T.et al. Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The S447X-Stop substitution in the lipoprotein lipase gene. Circulation. 95:1997;2628-2635.
18. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1978;499-502.
19. Faustinella F., Chang A., Biervliet J.P.V., Rosseneu M., Vinaimont N., Smith L.C.et al. Catalytic triad residue mutation (asp 156-Gly) causing familial lipoprotein lipase deficiency. J. Biol. Chem. 22:1991;14418-14424.
20. Kobayashi J., Nishida T., Ameis D., Stahnke G., Schotz M., Hashimoto H. et al. A heterozygous mutation (the codon for Ser 447-a stop codon) in lipoprotein lipase contributes to a defect in lipid interface recognition in a case with type I hyperlipidemia. Biochem. Biophys. Res. Comm. 182:1992;70-77.
21. Kozaki K., Gotoda T., Kawamura M., Shimano H., Yazaki Y., Ouchi Y.et al. Mutational analysis of human lipoprotein lipase by carboxy-terminal truncation. J. Lipid Res. 34:1993;1765-1772.
22. Maranhão R.C., Tercyak A.M., Redgrave T.G. Effects of cholesterol content on the metabolism of protein-free emulsion models of lipoproteins. Biochim. Biophys. Acta. 875:1986;247-255.
23. Redgrave T.G., Ly H.L., Quintão E.C., Ramberg C.F., Boston R.C. Clearance from plasma of triacylglycerol and cholesteryl ester after intravenous injection of chylomicron-like lipid emulsions in rats and man. Biochem. J. 290:1993;843-847.
24. Redgrave T.G., Maranhao R.C. Metabolism of protein-free lipid emulsion models of chylomicrons in rats. Biochim. Biophys. Acta. 835:1985;104-112.
25. Bernardes-Silva H., Toffoletto O., Bortolotto L.A., Latrilha C.M., Krieger E.M., Pileggi F.et al. Malignant hypertension is accompanied by marked alterations in chylomicron metabolism. Hypertension. 26:1995;1207-1210.
26. Borba E.F., Bonfa E., Vinagre C.G.C., Ramires J.A.F., Maranhão R.C. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum. 43:2000;1033-1040.
27. Vinagre C.G., Stolf N.A.G., Bocchi E., Maranhão R.C. Chylomicron metabolism in patients submitted to cardiac transplantation. Transplantation. 69:2000;532-537.
28. Oliveira M.R.M., Maranhão R.C. Plasma kinetics of a chylomicron-like emulsion in normolipidemic obese women after a short-period weight loss by energy-restricted diet. Metabolism. 2002.
29. Santos R.D., Sposito A.C., Ventura L.I., Cesar L.A.M., Ramires J.A.F., Maranhão R.C. Effect of provastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease. Am. J. Cardiol. 85:2000;1163-1166.
30. Sposito A.C., Maranhão R.C., Vinagre C.C.G., Santos R.D., Ramires J.A.F. Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. Atherosclerosis. 154:2001;455-461.
31. Yang J.Y., Kim T.K., Koo B.S., Park B.H., Park J.W. Change of plasma lipoproteins by heparin-released lipoprotein lipase. Exp. Mol. Med. 31:1999;60-64.
32. Leidig G.A. Jr., Pasternak R.C., Horowitz G., Ginsburg G.S. Effects of heparin and cardiac catheterization on serum lipoprotein and triglyceride levels. Am J. Cardiol. 74:1994;47-52.
33. Tornvall P., Olivecrona G., Karpe F., Hamsten A., Olivecrona T. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15:1995;1086-1093.